Immunoglobulins for multiple myeloma patients on BCMA T-cell engagers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have multiple myeloma and have had at least one prior treatment for it.
- You are currently receiving or about to start a type of immunotherapy called a BCMA-directed T-cell engager.
- You may or may not have received immunoglobulin support before.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This study looks at how the immune system changes in patients with multiple myeloma who have had treatment that targets a protein called BCMA. It may help doctors understand why some treatments stop working and how to improve future care.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Hear when a new Relapsed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.